EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC-ND 4.0

Comparative Risk of Hospitalized Bleeding of P2Y12 Inhibitors for Secondary Prophylaxis in Acute Coronary Syndrome After Percutaneous Coronary Intervention

Arun Kumar iD, Pamela L Lutsey iD, Wendy L St Peter iD, Jon C Schommer iD, Jeremy R Van't Hof iD, Abhijeet Rajpurohit iD, Joel F Farley iD

Clinical Pharmacology & Therapeutics · 2023-02 · 113 (2) · 412-422

DOI: 10.1002/cpt.2806 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 28.12.2022. Verfasst von Arun Kumar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice & Administrative Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, Ohio, USA. Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Percutaneous Coronary Intervention. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In closely monitored randomized controlled trials (RCTs), newer P2Y12 agents (ticagrelor and prasugrel) reduced cardiovascular outcomes compared with clopidogrel following percutaneous coronary intervention (PCI) in acute coronary syndrome. However, these RCTs indicated a higher bleeding risk with these newer agents. This study evaluated the comparative safety of each P2Y12 inhibitor on hospitalizations due to major bleeding in a real‐world population. This retrospective, propensity score‐matched (PSM) cohort study utilized the IBM MarketScan database over 6 years (2013–2018) to identify incident users of P2Y12 inhibitors with age ≥18 years. The primary safety outcome was hospitalization due to any major bleeding event including gastrointestinal, intracranial, and other serious forms of bleeding. In pairwise comparisons using Cox‐proportional hazards models, ticagrelor, prasugrel, and clopidogrel users were compared for the primary safety outcome at 30, 90, and 180 days following the first prescription of P2Y12 inhibitor after PCI. There were 21,719 (ticagrelor vs. clopidogrel), 11,513 (prasugrel vs. clopidogrel), and 11,065 (prasugrel vs. ticagrelor) PSM pairs. Overall, the risk of major bleeding was similar for all P2Y12 inhibitors. Hospitalization for major bleeding was generally lower among ticagrelor users vs. clopidogrel and higher among prasugrel users compared with clopidogrel. Importantly, a 66% higher risk of major bleeding at 90 days is suggested with prasugrel compared with clopidogrel (hazard ratio 1.66; 95% confidence interval, 1.11–2.48). This study indicated a higher short‐term bleeding risk with prasugrel compared with clopidogrel, which concurs with the results of RCTs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Coronary SyndromePercutaneous Coronary InterventionAdolescentHumansClopidogrelHemorrhagePlatelet Aggregation InhibitorsPrasugrel HydrochloridePurinergic P2Y Receptor AntagonistsTicagrelorTreatment Outcome

Substanzen

ClopidogrelPlatelet Aggregation InhibitorsPrasugrel HydrochloridePurinergic P2Y Receptor AntagonistsTicagrelor

Autor:innen und Institutionen

  • Department of Pharmacy Practice & Administrative Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, Ohio, USA.
  • Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA.
  • Department of Pharmaceutical Care and Health Systems, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.
  • Cardiovascular Division and Lillehei Heart Institute, University of Minnesota Medical School, Minneapolis, Minnesota, USA.

ORCID-Profile: Arun Kumar, Pamela L Lutsey, Wendy L St Peter, Jon C Schommer, Jeremy R Van't Hof, Abhijeet Rajpurohit, Joel F Farley

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Kumar, A., Lutsey, P. L., St Peter, W. L., Schommer, J. C., Van't Hof, J. R., Rajpurohit, A., & Farley, J. F. (2023). Comparative Risk of Hospitalized Bleeding of P2Y12 Inhibitors for Secondary Prophylaxis in Acute Coronary Syndrome After Percutaneous Coronary Intervention. Clinical Pharmacology & Therapeutics, 113(2), 412-422. https://doi.org/10.1002/cpt.2806

Vancouver

Kumar A, Lutsey PL, St Peter WL, Schommer JC, Van't Hof JR, Rajpurohit A, et al. Comparative Risk of Hospitalized Bleeding of P2Y12 Inhibitors for Secondary Prophylaxis in Acute Coronary Syndrome After Percutaneous Coronary Intervention. Clinical Pharmacology & Therapeutics. 2023;113(2):412-422. doi:10.1002/cpt.2806

BibTeX
@article{Kumar2023,
  author = {Kumar, Arun and Lutsey, Pamela L and St Peter, Wendy L and Schommer, Jon C and Van't Hof, Jeremy R and Rajpurohit, Abhijeet and Farley, Joel F},
  title = {Comparative Risk of Hospitalized Bleeding of P2Y12 Inhibitors for Secondary Prophylaxis in Acute Coronary Syndrome After Percutaneous Coronary Intervention},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2023},
  volume = {113},
  number = {2},
  pages = {412--422},
  doi = {10.1002/cpt.2806}
}
Kostenlos starten →